Skip to main content
Equibles
MED logo

MED · Medifast Inc

Track MED — free

Use MED with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about MED

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$12.16 -0.06 (-0.49%) At close · Aug 27
Market Cap
$135.90M
Shares
11.18M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.16 Open$12.28 Day$12.10–12.57 52W close$9.45–14.57 Avg vol 30d180K Short int1.8M · 16.3% float · 7.4d Short vol30% Last earningsAug 3, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 3

Up next

Next earnings call
Nov 2, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 3, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.5 · calm Equity put/call 0.39
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +9%
      above
      Price vs 50-day avg +11%
      above
      RSI (14) 60
      neutral
      MACD trend Positive
      52-week position 53%
      mid-range
      Momentum
      relative strength
      Very Strong
      1-month return +23%
      trailing
      6-month return +13%
      trailing
      YTD return +14%
      this year
      Relative strength −2%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $11 › 200d $11 — 200d above 50d
      Institutional flow Distributing
      -1% holders QoQ · +24 funds added
      Insider flow Accumulating
      Net +$894.6K over 90 days · 0% sells
      Short interest Rising
      16.32% of float · ▲ +22.9% MoM · 7.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      114 holders — near 3-yr low, contrarian setup
      Squeeze score 85
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +31%
      Y/Y
      Gross margin 29%
      contracting
      EPS growth −995%
      Y/Y
      Free cash flow $1.2M
      Buyback $20.0M
      remaining
      Balance sheet $89.3M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 53%
      annualized · 1-yr
      Max drawdown −35%
      past year
      ATR 4.1%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 7 of last 8
      Latest guidance · from the 8-K filed Aug 3, 2026
      Revenue · full year 2026 Maintained $270M – $300M
      Jun 30, 2026 $270M – $300M changed to Aug 3, 2026 $270M – $300M
      prior FY $385.79M midpoint −26.1% Y/Y
      Prior guidance period ended · from the 8-K filed May 4, 2026
      Revenue · second quarter 2026 $60M – $80M
      Guided vs delivered · last 8 settled
      Revenue second quarter 2026
      guided $60M – $80M
      $76.38M In line
      Revenue fourth quarter 2025
      guided $65M – $80M
      $75.1M In line
      Revenue third quarter 2025
      guided $70M – $90M
      $89.41M In line
      Diluted income/(loss) per share third quarter 2025
      guided $-0.60 – $0.00
      $-0.21 In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 3 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +9% Bullish
      Price vs 50-day avg
      +11% Bullish
      RSI (14)
      60 Neutral
      MACD trend
      Positive Bullish
      52-week position
      53% Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $11 › 200d $11 — 200d above 50d
      Institutional flow Distributing
      -1% holders QoQ · +24 funds added
      Insider flow Accumulating
      Net +$894.6K over 90 days · 0% sells
      Short interest Rising
      16.32% of float · ▲ +22.9% MoM · 7.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      114 holders — near 3-yr low, contrarian setup
      Price context
      position in its 52-week range
      Range low $9 Now $12 · 53% Range high $15
      vs 200-day avg +9% vs 50-day avg +11%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Average revenue per active earning coach $4,664 fourth quarter 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Personal Services — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      MED
      Medifast Inc
      this stock
      		$135.90M +13.9% +31.0% — 16.3%
      ROL
      Rollins Inc
      		 $17.66B -40.1% +7.2% 33.4 2.7%
      SCI
      Service Corp International
      		 $11.66B +7.1% +2.9% 22.3 3.7%
      HRB
      H&R Block Inc
      		 $6.47B +20.5% -1.3% — 14.5%
      ANDG
      Andersen Group Inc.
      		 $6.00B +118.1% +14.6% — 2.2%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      114
      % held
      83.1%
      Net QoQ
      -962.4K sh
      Top holder
      RENAISSANCE TECHNOLOGIES…
      Held Float
      View
      Held by Funds
      Fund positions
      127
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      1.8M
      Days to cover
      7.4d
      Change
      +339.8K sh
      View
      Short Volume
      Short vol %
      30%
      As of
      Aug 27, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      20
      Value
      $193
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      44.0%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$894.6K
      Buyers / Sellers
      1 / 0
      Buyers Sellers
      View
      Congressional Trades Sell
      Member
      Donna Shalala
      Amount
      $1.0K–$15.0K
      Traded
      Jun 24, 2019
      View
      Financials
      Financials
      Revenue (FY)
      $385.8M
      Net income (FY)
      $-18.7M
      EPS diluted
      $-1.70
      View
      Buybacks
      Authorized
      $100.0M
      Remaining
      $20.0M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 3, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $159.9K
      Shares
      4.1K
      Filed
      Mar 8, 2024
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 3, 2026
      View
      Investor Relations
      Latest news
      Medifast® Announces the Launch of…
      Published
      Aug 27, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      MED +4.7% +22.7% +12.9% +23.7% +13.9%
      SPY +1.1% +4.0% +14.7% +3.2% +13.1%
      vs SPY +3.5% +18.7% -1.8% +20.5% +0.8%

      Capital returns

      Latest dividend
      $1.65 / share · ex Sep 18, 2023
      Raised 0.6%
      Paid (TTM)
      $0.00 / share · 0 payouts
      Dividend yield (TTM, derived)
      — · no payout in the trailing year
      Buyback program · as of Jun 30, 2022
      Authorized
      $100.00M
      Spent (derived)
      $80.00M
      Remaining
      $20.00M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 910329 CUSIP 58470H101 13F (30d) 101 filings 98 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)